EUVIMEDEUVIMED entdecken
ValidierungsstudieOpen Access · CC BY 4.0

Development and validation of an ultrafast method of quantification of rivaroxaban in human serum using laser diode thermal desorption coupled to triple quadrupole mass spectrometry

Mégane Moreau, Serge Auger, Pierre Picard, Jean Lacoursière, Pedro A Segura iD

Rapid Communications in Mass Spectrometry · 2024

DOI: 10.1002/rcm.9855 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift Rapid Communications in Mass Spectrometry, 2024. Verfasst von Mégane Moreau und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Université de Sherbrooke, Sherbrooke, QC, Canada. Hauptthemen laut MEDLINE: Rivaroxaban, Tandem Mass Spectrometry. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rationale

Rivaroxaban is an anticoagulant prescribed to patients who are at risk of medical conditions such as deep‐vein thrombosis, pulmonary embolisms, and strokes caused by blood clots. The administration of this drug is monitored to adjust the dosage and evaluate patients' blood concentration. Rapid quantification of this drug in plasma could make it possible to ensure that the dose present in the blood of patients does not represent a danger for the medical intervention to be carried out.

Methods

Liquid chromatography–tandem mass spectrometry is usually employed to quantify rivaroxaban in blood, plasma, and serum. Here, an alternative method of analysis based on laser diode thermal desorption–triple quadrupole mass spectrometry (LDTD‐QqQMS) was developed and comprehensively validated. This new method allows the quantification of rivaroxaban in less than 13 s from sample to sample. The extraction of rivaroxaban in human serum was done by a salting‐out liquid–liquid extraction with acetonitrile and a saturated sodium chloride solution.

Results

The proposed method allows the quantification of rivaroxaban in less than 13 s from sample to sample. During validation, all criteria were respected. The accuracy was

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RivaroxabanTandem Mass SpectrometryHumansReproducibility of ResultsLimit of DetectionSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationLinear Models

Substanzen

Rivaroxaban

Autor:innen und Institutionen

  • Department of Chemistry, Université de Sherbrooke, Sherbrooke, QC, Canada.
  • Phytronix Technologies, Québec, Canada.

ORCID-Profile: Pedro A Segura

Zitieren

APA

Moreau, M., Auger, S., Picard, P., Lacoursière, J., & Segura, P. A. (2024). Development and validation of an ultrafast method of quantification of rivaroxaban in human serum using laser diode thermal desorption coupled to triple quadrupole mass spectrometry. Rapid Communications in Mass Spectrometry. https://doi.org/10.1002/rcm.9855

Vancouver

Moreau M, Auger S, Picard P, Lacoursière J, Segura PA. Development and validation of an ultrafast method of quantification of rivaroxaban in human serum using laser diode thermal desorption coupled to triple quadrupole mass spectrometry. Rapid Communications in Mass Spectrometry. 2024. doi:10.1002/rcm.9855

BibTeX
@article{Moreau2024,
  author = {Moreau, Mégane and Auger, Serge and Picard, Pierre and Lacoursière, Jean and Segura, Pedro A},
  title = {Development and validation of an ultrafast method of quantification of rivaroxaban in human serum using laser diode thermal desorption coupled to triple quadrupole mass spectrometry},
  journal = {Rapid Communications in Mass Spectrometry},
  year = {2024},
  doi = {10.1002/rcm.9855}
}
Kostenlos starten →